Impact of Bone Marrow Fibrosis on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 Aug 27

PMID 39192082

Authors

Haixiao Zhang

Wenwen Guo

Jiali Wang

Ni Lu

Xinhui Zheng

Qi Sun

Yonghui Xia

Rongli Zhang

Xin Chen

Qiaoling Ma

Donglin Yang

Aiming Pang

Jialin Wei

Yi He

Sizhou Feng

Mingzhe Han

Weihua Zhai

Erlie Jiang

Affiliations

Soon will be listed here.

Abstract

Bone marrow fibrosis (BMF) of unknown etiology was common in hematological malignancies, but its prognostic value for acute myeloid leukemia (AML) is unclear. We interrogated data from 532 newly diagnosed subjects with AML receiving allogeneic hematological stem cell transplantation to evaluate the prognostic impact of BMF on transplant outcomes. Using the European consensus on the grading of BMF at diagnosis, 255 (48%) subjects were BMF-0, 209 (39%), BMF-1 and 68 (13%), BMF-2-3. Subjects with BMF-2-3 had poor overall survival (P < 0.001), disease-free survival (P < 0.001) and a higher incidence of relapse (CIR, P < 0.001). Multi-variable analyses in subjects achieving pre-transplant complete remission showed BMF-2-3 was an independent risk factor for CIR (Hazard Ratio [HR] = 2.17, (95% CI, 1.11, 4,24); P = 0.02). Furthermore, BMF-2-3 group showed delayed neutrophil and platelet engraftment and delayed B cell recovery post-transplantation. These findings demonstrate the significance of BMF in transplant outcomes and attract more attention to AML with BMF.

References

Zhang Y, Wu J, Qin T, Xu Z, Qu S, Pan L . Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia. 2022; 36(12):2875-2882. PMC: 9712101. DOI: 10.1038/s41375-022-01718-7. View

Harris A, Young R, Devine S, Hogan W, Ayuk F, Bunworasate U . International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2015; 22(1):4-10. PMC: 4706482. DOI: 10.1016/j.bbmt.2015.09.001. View

Thol F, Dohner H, Ganser A . How I treat refractory and relapsed acute myeloid leukemia. Blood. 2023; 143(1):11-20. DOI: 10.1182/blood.2023022481. View

Xuan L, Liu Q . Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021; 14(1):4. PMC: 7786934. DOI: 10.1186/s13045-020-01017-7. View

Hamilton B, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E . Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. Am J Hematol. 2016; 91(4):406-9. DOI: 10.1002/ajh.24306. View

Croxford J, Tang M, Pan M, Huang C, Kamran N, Phua C . ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood. 2013; 121(13):2512-21. PMC: 4260366. DOI: 10.1182/blood-2012-08-449025. View

Yao J, Zhang G, Liang C, Li G, Chen X, Ma Q . Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission. Leuk Res. 2017; 55:97-104. DOI: 10.1016/j.leukres.2017.01.026. View

Zhai Y, Zhang J, Wang H, Lu W, Liu S, Yu Y . Growth differentiation factor 15 contributes to cancer-associated fibroblasts-mediated chemo-protection of AML cells. J Exp Clin Cancer Res. 2016; 35(1):147. PMC: 5029001. DOI: 10.1186/s13046-016-0405-0. View

Della Porta M, Malcovati L . Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011; 96(2):180-3. PMC: 3031682. DOI: 10.3324/haematol.2010.039875. View

10.

Jacobson R, Salo A, Fialkow P . Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978; 51(2):189-94. View

11.

Torlen J, Gaballa A, Remberger M, Mork L, Sundberg B, Mattsson J . Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(6):1260-1268. DOI: 10.1016/j.bbmt.2019.01.029. View

12.

Wang J, Wang Q, Zhang H, He Y, Huang Y, Zhang R . Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021; 27(8):666.e1-666.e9. DOI: 10.1016/j.jtct.2021.05.006. View

13.

Scott B, Storer B, Greene J, Hackman R, Appelbaum F, Deeg H . Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007; 13(3):345-54. DOI: 10.1016/j.bbmt.2006.10.030. View

14.

Small T, Papadopoulos E, Boulad F, Black P, Castro-Malaspina H, Childs B . Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999; 93(2):467-80. View

15.

Storek J, Dawson M, Storer B, Stevens-Ayers T, Maloney D, Marr K . Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001; 97(11):3380-9. DOI: 10.1182/blood.v97.11.3380. View

16.

Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P . The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023; 202(2):279-283. DOI: 10.1111/bjh.18850. View

17.

Wu Z, Chen R, Wu L, Zou L, Ding F, Wang M . Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia. Clin Transl Oncol. 2017; 19(12):1462-1468. DOI: 10.1007/s12094-017-1687-1. View

18.

Zhang X, Wang F, Yu J, Jiang Z . Significance of bone marrow fibrosis in acute myeloid leukemia for survival in the real-world. Front Oncol. 2022; 12:971082. PMC: 9585239. DOI: 10.3389/fonc.2022.971082. View

19.

Spyridonidis A, Labopin M, Savani B, Niittyvuopio R, Blaise D, Craddock C . Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020; 55(6):1114-1125. DOI: 10.1038/s41409-020-0803-y. View

20.

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View